NEW YORK, June 14 – Gene Logic has invested in Metabometrix, a London-based startup studying metabolites in human fluids, and will partner with the company to link gene expression information with metabolite data, the companies said Thursday.
The companies did not disclose the amount of the equity investment, or other financial details.
Metabometrix uses NMR and flow-injection technology to study how metabolites--the break-down products of proteins involved in cellular pathways--change in response to disease or therapy. The company says its technology is useful for drug toxicity and efficacy screening, clinical diagnostics, and environmental science.
The research collaboration will focus initially on adding metabolite information to Gene Logic’s toxicology database, which the company hopes will allow pharmaceutical companies to rank potential therapeutics according to their toxicity.
"We are pleased to make this initial investment in Metabometrix and anticipate identifying the relationship between genomic and metabonomic markers for human disease and toxicity," Mark Gessler, CEO of Gene Logic, said in a statement.